About: SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems
Creator	Liu, Wen-Chun Albrecht, Randy Tenoever, Benjamin Blanco-Melo, Daniel Møller, Rasmus Nilsson-Payant, Benjamin Panis, Maryline Sachs, David
source	BioRxiv
abstract	One of the greatest threats to humanity is the emergence of a pandemic virus. Among those with the greatest potential for such an event include influenza viruses and coronaviruses. In the last century alone, we have observed four major influenza A virus pandemics as well as the emergence of three highly pathogenic coronaviruses including SARS-CoV-2, the causative agent of the ongoing COVID-19 pandemic. As no effective antiviral treatments or vaccines are presently available against SARS-CoV-2, it is important to understand the host response to this virus as this may guide the efforts in development towards novel therapeutics. Here, we offer the first in-depth characterization of the host transcriptional response to SARS-CoV-2 and other respiratory infections through in vitro, ex vivo, and in vivo model systems. Our data demonstrate the each virus elicits both core antiviral components as well as unique transcriptional footprints. Compared to the response to influenza A virus and respiratory syncytial virus, SARS-CoV-2 elicits a muted response that lacks robust induction of a subset of cytokines including the Type I and Type III interferons as well as a numerous chemokines. Taken together, these data suggest that the unique transcriptional signature of this virus may be responsible for the development of COVID-19.
has issue date	2020-03-24(xsd:dateTime)
bibo:doi	10.1101/2020.03.24.004655
has license	biorxiv
sha1sum (hex)	817fe8b5b1f43b114b5802f168d6294607b3f825
schema:url	https://doi.org/10.1101/2020.03.24.004655
resource representing a document's title	SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems
schema:publication	bioRxiv
resource representing a document's body	covid:817fe8b5b1f43b114b5802f168d6294607b3f825#body_text
is schema:about of	named entity 'transcriptional' named entity 'SARS-CoV-2' named entity 'induction' named entity 'therapeutics' named entity 'demonstrate' covid:arg/817fe8b5b1f43b114b5802f168d6294607b3f825 named entity 'century' named entity 'pandemics' named entity 'numerous' named entity 'treatments' named entity 'core' named entity 'transcriptional' named entity 'potential' named entity 'humanity' named entity 'antiviral' named entity 'vaccines' named entity 'response' named entity 'systems' named entity 'antiviral' named entity 'virus' named entity 'influenza A virus' named entity 'SARS-CoV-2' named entity 'transcriptional' named entity 'chemokines' named entity 'antiviral' named entity 'interferons' named entity 'COVID-19 pandemic' named entity 'influenza A virus' named entity 'transcriptional' named entity 'SARS-CoV-2' named entity 'BSG' named entity 'mRNA' named entity 'IAV' named entity 'MOI' named entity 'IFN' named entity 'health crisis' named entity 'interferon' named entity 'COVID-19' named entity 'asymptomatic' named entity 'TMPRSS2' named entity 'multiplicity of infection' named entity 'viruses' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'EDN1' named entity 'morbidity' named entity 'human coronaviruses' named entity 'polyA RNA' named entity 'Type II pneumocytes' named entity 'case-fatality rate' named entity 'SARS-CoV-2' named entity 'lungs' named entity 'CXCL10' named entity 'SARS-CoV-2' named entity 'IAV' named entity 'molecular basis' named entity 'ACE2' named entity 'viral replication' named entity 'SARS-CoV-2' named entity 'transcriptional' named entity 'DDX58' named entity 'IFN' named entity 'physiological response' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'cell line' named entity 'IFN' named entity 'viruses' named entity 'transcriptional' named entity 'antiviral' named entity 'RSV' named entity 'viruses' named entity 'RSV' named entity 'infection' named entity 'cell line' named entity 'alveolar cells' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software